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ABSTRACT Primary ciliary dyskinesia (PCD) is a genetic, heterogeneous disease caused by dysfunction
of cilia. Evidence is sparse and reports of lung function in PCD patients range from normal to severe
impairment. This systematic review and meta-analysis of studies of lung function in PCD patients
examines the spirometric indices of PCD patients and differences by age group and sex.
We searched PubMed, Embase and Scopus for studies that described lung function in 10 or more
patients with PCD. We performed meta-analyses and meta-regression to explain heterogeneity. We
included 24 studies, ranging from 13 to 158 patients per study.
The most commonly reported spirometric indices were forced expiratory volume in 1 s (FEV1) and
forced vital capacity presented as mean and standard deviation of percent predicted values. We found
considerable heterogeneity for both parameters (I2=94–96%). The heterogeneity remained when we
stratified the analysis by age; however, FEV1 in adult patients was lower. Even after taking into account
explanatory factors, the largest part of the between-studies variance remained unexplained.
Heterogeneity could be explained by genetic differences between study populations, methodological
factors related to the variability of study inclusion criteria or details on the performance and evaluation of
lung function measurements that we could not account for. Prospective studies therefore need to use
standardised protocols and international reference values. These results underline the possibility of distinct
PCD phenotypes as in other chronic respiratory diseases. Detailed characterisation of these phenotypes
and related genotypes is needed in order to better understand the natural history of PCD.
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PRIMARY CILIARY DYSKINESIA
Introduction
Primary ciliary dyskinesia (PCD) is a genetic, heterogeneous disease caused by absence and/or dysfunction
of cilia [1]. Its prevalence is estimated to be around 1 in 10000, but it is underdiagnosed [2]. It can affect
ciliated cells throughout the body and lead to numerous manifestations, primarily in the respiratory system [3].
Most patients suffer from chronic and recurrent upper respiratory infections from early in life, which can
lead to lung damage and bronchiectasis as the disease progresses [1, 4].
Lung function is one of the most important predictors of overall survival among both healthy individuals and
patients with chronic lung disease [5]. Spirometry, which is widely available, is the easiest and most common
method of testing pulmonary function. Spirometric indices, primarily forced expiratory volume in 1 s (FEV1),
are used to monitor progression and describe severity in chronic respiratory diseases such as cystic fibrosis or
chronic obstructive pulmonary disease [6–8]. In PCD patients, several studies have reported results of lung
function measurements; however, their findings are contradictory, ranging from normal lung function to
significant impairment. Most studies have focused on paediatric or young adult patients and reports from
older patients are rare. Data on sex differences are also scarce, although evidence is growing that a number of
pulmonary diseases affect females and males differently [9]. A detailed overview and comparison of existing
studies of lung function is necessary to inform PCD research about existing and improved use of spirometry,
and to determine where more evidence is needed in the study and treatment of PCD.
This systematic review and meta-analysis therefore identifies all published studies presenting lung function in
patients with PCD, and it summarises spirometric indices reported in those studies. We also identify differences
in these spirometric indices between male and female patients and between paediatric and adult patients.
Methods
The protocol we developed for the systematic review is summarised here. We followed the PRISMA
guidelines for reporting [10].
Search strategy
We searched PubMed, Embase and Scopus with no restriction of language or study design for studies
published between January 1980 and February 2017 that described lung function in patients with PCD
(Orphanet classification ORPHA:244).
We tested multiple search terms to decide on the most appropriate term for each database. We selected the
most concise terms that identified the largest number of studies.
PubMed: ((“kartagener syndrome”[Title/Abstract] OR “primary ciliary dyskinesia”[Title/Abstract] OR
“ciliary motility disorders”[MeSH Terms]) AND (“lung function” OR “respiratory function” OR
“pulmonary function” OR “lung volume” OR “forced vital capacity” OR “forced expiratory volume” OR
“FEV” OR “FEV1” OR “spirometry” OR “wash out” OR “Follow-Up Studies” [MeSH] OR “Respiratory
Function Tests” [MeSH])).
Embase: “primary ciliary dyskinesia”:ab,ti OR “kartagener”:ab,ti OR “kartageners”:ab,ti OR “ciliary motility
disorder”:ab,ti AND (“lung function” OR “respiratory function” OR “pulmonary function” OR “lung
volume” OR “spirometry” OR “fev” OR “forced expiratory volume” OR “forced vital capacity” OR “fev1”
OR “plethysmography” OR “wash out”).
Scopus: ((TITLE-ABS-KEY(“primary ciliary dyskinesia”)) OR (TITLE-ABS-KEY(“kartagener”)) OR
(TITLE-ABS-KEY(“ciliary motility disorder”))) AND ((“wash out”) OR ((“lung function”) OR (“lung
volume”) OR (“respiratory function”) OR (“pulmonary function”) OR (“forced vital capacity” OR fvc) OR
(“forced expiratory volume”) OR (“spirometry”))).
After identifying all eligible studies, we checked for additional citations in their reference lists. We used
Endnote X5 (Thomson Reuters, Philadelphia, PA, USA) citation manager.
Definition of PCD patients
The diagnosis of PCD has changed over the period from 1980 to present [11, 12]. The studies we included
have a wide range of patient inclusion criteria, ranging from patients with a clinical diagnosis (in most
cases Kartagener syndrome) to those with positive results from tests that have varied with diagnostic
consensus at the time of each study: electron microscopy, light or high-speed video-microscopy, nasal
nitric oxide (nNO) and genetic testing.
Study selection
We included studies reporting lung function of patients with PCD that had a study population of 10 or
more patients. We excluded animal studies and those that were not original, studies that described
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diagnostic test results or genetics, but lacked information on lung function, and those that reported on
other rare ciliary syndromes, such as Joubert syndrome.
We initially screened publication titles and abstracts. From our experience with PCD literature [3], we
realised that many studies of PCD patients report lung function measurements without explicitly
articulating this in the title or abstract. Thus, we also screened the full text of original clinical studies of
PCD patients even if lung function was not mentioned in the title or abstract. After reading the full text of
all potentially eligible studies, the final decision on inclusion was made by two independent reviewers, one
with extensive experience in systematic reviews and knowledge of the disease. In case of disagreement, a
consensus decision was reached after discussion. During the final step of inclusion, we excluded studies
that did not report any spirometric indices and conference abstracts that lacked full text.
Overlapping study population
To avoid including the same patients multiple times in our review, we identified all studies that appeared
to share the same study population. We compared the author list, country of origin and department where
the study took place. In case we noticed a considerable overlap in the study population between two or
more studies, we always included in the quantitative synthesis the study that was published most recently
and included information on a larger number of patients. When two studies were published ⩾10 years
apart, we included both since we believed there would be little chance of significant overlap. Where the
extent of possible overlap was not clear, we contacted the study investigators for clarification.
Data extraction
We used Epidata version 3.1 (www.epidata.dk) to extract information from all studies, including those with
overlapping populations. We extracted 1) author- and publication-specific information, which included
author names, journal and year of publication, country, and centre of corresponding author; 2) study
characteristics, which included years the study was carried out, study design, inclusion and exclusion
criteria, study population size, country where the study took place, type of clinic, age of participants, and
age stratification of reported lung function measurements; and 3) information on spirometry of PCD
patients. For spirometry, we extracted all information reported on lung function measurements, including
values of spirometric indices and information on equipment used for spirometry, quality control measures
and reference values.
Meta-analysis
We performed meta-analyses of FEV1 and forced vital capacity (FVC), the most commonly reported
spirometry indices, using a DerSimonian–Laird random effects model [13, 14], and assessed the
heterogeneity (I2) between studies [15]. We assessed possible differences in lung function between children
and adults by performing separate subgroup meta-analyses in adults and children. Studies that did not
report FEV1 and FVC separately for adults and children or in which information on age was not available
were excluded from this subgroup analysis.
We then investigated reasons for heterogeneity by fitting meta-regression models. We considered the
following explanatory factors one at a time: period of publication (before 1997, 1997–2007, after 2007),
number of patients included in the study (<20, 21–50, 51–100, >100 patients), retrospective or prospective
study design, reference values used for spirometry (references using ⩾5000 subjects, <5000 subjects, no
information) [16], pulmonary function test quality control (based on European Respiratory Society (ERS)/
American Thoracic Society (ATS) guidelines, used the best out of three valid measurements, no
information available) and whether spirometry was the main study outcome (no, yes) [17].
Statistical analysis was performed with R version 3.1.2 (www.r-project.org) using the package meta version
4.3-2, specifically the commands metagen and metareg.
Results
Search
After excluding duplicates appearing in more than one of the databases (PubMed, Embase and Scopus),
our initial search produced 664 articles (figure 1). We screened the titles and abstracts of these, and
excluded 501 articles. Among the remaining 163 studies, 37 were either conference abstracts only or it was
not possible to find the full text. After reading the full text of the remaining 126 studies, we excluded
another 102 articles (figure 1), including 34 that had overlapping study populations [18–50]. Finally, we
included 24 studies reporting spirometric indices of PCD patients in the meta-analysis.
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Study characteristics and information on spirometry
Table 1 lists the 24 studies and their characteristics [4, 51–73]. The articles encompassed a total of 1179
patients with a mean (range) number of 49 (13–158) patients per study. Most studies were relatively small,
with 18 of the 24 including less than 50 patients (table 2). Nearly all studies originated from paediatric or
adult pulmonology departments, or from specialised PCD centres. 17 were single-centre studies. 15 were
published in the last 10 years (after 2007). 15 came from Europe, six from Asia and three were from North
or South America. Seven studies included only children (age <18 years), three only adults (age ⩾18 years)
and 14 studies had populations of mixed age consisting mainly of children with a few adults.
PCD diagnosis was established in different ways. 19 studies assessed ciliary ultrastructure using electron
microscopy and/or a combination of one or more of nNO, video-microscopy and genetics according to
available consensus at the time of each publication (table 2). In three of the 24 studies, the majority of
patients were similarly diagnosed on the basis of ciliary ultrastructure, although a small proportion of the
patients were diagnosed based only on strong clinical suspicion, mainly Kartagener syndrome. In two, older
studies, all patients were diagnosed based on strong clinical suspicion, again primarily Kartagener syndrome.
All studies reported FEV1 measurements and half of them also reported FVC measurements. How
investigators reported lung function measurements varied. The most commonly reported spirometric
indices were FEV1 and FVC, presented as mean and standard deviation of percent predicted values. In
studies in which FEV1 and FVC were reported differently or important information was not reported, we
contacted the investigators for additional data. Among the 14 studies that included both paediatric and
adult patients, only six of the 14 reported lung function results stratified by age groups. Only four of the
24 studies reported FEV1 and FVC as z-scores. Eight also reported other lung function measurements
such as plethysmography and multiple-breathe washout techniques or exhaled breath analysis techniques.
Investigators used a variety of different spirometry reference values depending on the year of publication;
10 out of the 24 studies did not report which references were used for the calculation of the percent
predicted values. 12 of the studies reported that spirometry was performed based on the ERS/ATS
guidelines, while in five more the best of three acceptable spirometry measurements was chosen. The
remaining seven studies did not report on quality measures of spirometry. Only seven of the 24 studies
included longitudinal measurements of lung function.
Supplementary table S1 presents the characteristics of all included studies and studies with overlapping
populations.
Forced expiratory volume in 1 s
Reported FEV1 values varied significantly between the studies and mean FEV1 % pred ranged from 51% to
96%. Weighted mean FEV1 % pred in the 24 studies was 75% (95% CI 69–80%) with a heterogeneity of
I2=96% (figure 2). Results remained the same when we excluded from the meta-analysis the two studies
Studies identiﬁed and abstracts screened
(n=664)
Studies excluded based on their abstracts (n=501)
  Not original studies (n=184)
  Not topic related (n=20)
  Not lung function (n=140)
  Less than 10 patients (n=148)
  Animal studies (n=9)
No full text available (n=37)
Full-text articles excluded (n=68)
  Not original studies (n=31)
  Not topic related (n=9)
  Not lung function/spirometry (n=19)
  Less than 10 patients (n=9)
Overlapping study population (n=34)
Full-text articles assessed for eligibility
(n=163)
Studies included
in qualitative and quantitative synthesis
(n=24)
FIGURE 1 Flowchart describing the selection procedure.
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TABLE 1 Detailed characteristics of included studies describing spirometric indices of primary ciliary dyskinesia patients, stratified by age group of patients
First author [ref.] Country Year of
publication
Patients
n
Age years Type of
study
Study
design
Diagnostics Symptoms
stratified by
age
Longitudinal
data
FEV1 FVC
Children
AL SAADI [51] Saudi Arabia 2013 22 10.86±3.09# Prospective Case–control EM+HFVM NA − + −
DAVIS [55] USA/Canada 2015 118 8 (5–11)¶ Prospective Case series EM or genetic
analysis
NA − + −
GOKDEMIR [58] Turkey 2014 24 12.9±2.7# Prospective Clinical trial EM or Kartagener NA − + +
KARADAG [61] UK 1999 21 10.8±3.2# Retrospective Case–control EM, HFVM NA − + +
KOH [62] Korea 2000 19 12 (7–16)+ Prospective Clinical trial EM NA − + −
MAGLIONE [63] Denmark, Italy and
UK
2014 158 8.7 (4.2–17.4)§ Retrospective Cohort According to
consensus
NA + + +
PAFF [68] The Netherlands 2013 25 10.7 (7.1–14.5)¶ Prospective Case–control According to
consensus
NA − + −
Adults
FRIJA-MASSON [57] France 2017 78 34.8 (28.6–47.1)¶ Retrospective Case series EM, genetic
analysis or
Kartagener
NA + + +
HORVATH [60] UK 2003 14 35±4.6# Prospective Case–control EM, HFVM NA − + +
MOSSBERG [65] Sweden 1983 24 30 (19–47)§ Prospective Case series Clinical suspicion NA − + −
Both children
and adults
AMIRAV [52] Israel 2016 13 10 (5–43)¶ Retrospective Case series All tests, including
genetic analysis
− − + −
BOON [53] Belgium 2014 122 17.7 (9.5–28.1)¶ Retrospective Case series EM, HFVM, genetic
analysis
− − + +
COHEN-CYMBERKNOH [54] Israel 2014 14 15.9±8.6# Retrospective Case series EM, HFVM, nNO,
genetic analysis
− − + −
ELLERMAN [56] Denmark 1997 24 21±13.6# Prospective Case series HFVM + + + +
HELLINCKX [59] Belgium 1998 11 15.2±7# Prospective Case series EM, HFVM + + + −
MAHUT [64] France 2006 16 13.5 (12–17)¶ Retrospective Case series Clinical, EM + − + −
NOONE [4] USA and Canada 2004 78 Adults: 36 (19–73)+;
children: 8 (1–17)+
Prospective Case series EM, HFVM, genetic
analysis
+ − + −
NYILAS [66] Germany and
Switzerland
2017 49 14.7±6.6# Prospective Case–control All tests − − + +
OLM [67] Brazil 2011 10 13.4±4.7# Prospective Case–control EM+HFVM + − + +
PIFFERI [69] Italy 2015 45 14 (22.25)¶ Prospective Case–control EM, HFVM, nNO − − + +
SHAH [70] UK 2016 118 23.5 (10–36)¶ Retrospective Case series EM, HFVM, nNO,
2% clinical
− + + −
TOLUSAKOW [71] Germany 1981 21 3–43ƒ Retrospective Case series Clinical suspicion − − + +
VALLET [72] France 2013 41 6 (3–11)¶ Retrospective Case series EM, HFVM − + + +
YIALLOUROS [73] Cyprus 2015 20 0.1–58.4ƒ Retrospective Case series EM or HFVM+nNO + + + +
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; EM: electron microscopy; HFVM: high-frequency video-microscopy; NA: not applicable; nNO: nasal nitric oxide. Age is
reported in different formats depending on the available information: #: mean±SD; ¶: median (interquartile range); +: median (range); §: mean (range); ƒ: range.
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having only clinically diagnosed patients. In the subgroup meta-analyses, including the 16 studies with
information on age groups, eight studies reported FEV1 measurements in patients aged ⩾18 years and 13
reported FEV1 measurements in children aged <18 years. In adults, mean FEV1 % pred values ranged
from 44% to 79% with a weighted mean value of 63% (95% CI 57–69%) and I2=91% (figure 3). In
children, mean FEV1 % pred values ranged from 73% to 96% with a weighted mean value of 81% (95% CI
78–83%) and I2=78% (figure 3).
Forced vital capacity
In the 13 studies including FVC % pred results, reported values ranged from 66% to 92%. Weighted mean
FVC % pred was 83% (95% CI 78–89%) with a heterogeneity of I2=94% (figure 4). In the subgroup
meta-analyses, we included four studies reporting FVC measurements for patients aged ⩾18 years and six
studies of children aged <18 years. In adults, mean FVC % pred values ranged from 70% to 94% with a
weighted mean value of 79% (95% CI 70–88%) and I2=89% (supplementary figure S1). In children, mean
FVC % pred values ranged from 77% to 90% with a weighted mean value of 85% (95% CI 80–90%) and
I2=72% (supplementary figure S1).
Meta-regression
Meta-regressions showed that the explanatory factors explained only a small part of the between-studies
variance for all symptoms. Studies published after 2007 reported higher mean values of FEV1 and FVC
(both p=0.01). Another factor that explained part of the heterogeneity was the reference values for
TABLE 2 Characteristics of included studies describing spirometry indices of primary ciliary
dyskinesia patients
Total studies 24 (100)
Study size
⩽20 patients 8 (33)
21–50 patients 10 (42)
51–100 patients 2 (8)
>100 patients 4 (17)
Number of centres
Single centre 17 (71)
Multicentre 7 (29)
Publication period
⩽1996 2 (8)
1997–2007 7 (29)
⩾2008 15 (63)
Study region
Europe 15 (62.5)
Asia 6 (25)
North and South America 3 (12.5)
Age of participants
Children <18 years 7 (29)
Adults ⩾18 years 3 (13)
Children and adults 14 (58)
Study design
Retrospective 11 (46)
Prospective 13 (54)
Diagnostics performed
Diagnosis based only on strong clinical suspicion 2 (8)
Diagnosis based on EM or a combination of tests in most patients;
few only on strong clinical suspicion#
3 (13)
Diagnosis based on EM or a combination of tests in all patients# 19 (79)
Spirometry indices reported
FEV1 24 (100)
FVC 12 (50)
Information for different age groups 6 (43)¶
Longitudinal information 8 (33)
Data are presented as n (%). EM: electron microscopy; FEV1: forced expiratory volume in 1 s; FVC: forced
vital capacity. #: combination of the following: EM, nasal nitric oxide, high-frequency video-microscopy or
light microscopy, or genetic analysis. ¶: of 14 studies including children and adults.
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spirometry. Studies that did not report the reference values they used reported lower mean values for both
FEV1 and FVC (p=0.003 and p=0.002, respectively). Mean FEV1 was lower in studies that did not include
any information on pulmonary function test quality control (p=0.02). Detailed results of the
meta-regression models are presented in supplementary table S2.
Differences between males and females
Only two of the 24 studies compared lung function of male and female patients. In a large cohort of
French adult patients, the spirometric indices of females were lower than those of males at the end of the
study and the annual decline of FEV1 was also greater in females [57]. In contrast, no difference by sex
was reported in a large British adult cohort [70].
Longitudinal data
Finally, although a preponderance of PCD studies made cross-sectional assessments, seven of the 24
studies in our meta-analysis followed lung function of PCD patients longitudinally, as did a further five of
the 34 studies in which we observed overlapping populations. The differing designs and follow-up times of
these 12 longitudinal studies disallow pooling their results in a meta-analysis. However, we offer a
qualitative overview of the findings reported in them.
Four studies reported that most patients had stable spirometric indices (FEV1 and FVC) during respective
short-term or longer follow-ups [56, 59, 63, 72]. Four other more recent studies including adult patients
reported important declines of FEV1 and/or FVC [27, 40, 57, 70]. A study of the Danish national cohort
of PCD patients [25] reported at least a 10% decrease in FEV1 % pred in one-third of the patients,
although great variation in lung function was observed after follow-up. In the British adult cohort, an
ultrastructural defect was associated with lung function decline: patients with a microtubular defect
reported a steeper decline [70], a finding that was not consistent with the results of a study of 60 French
children with PCD [72]. Larger national or multicentre studies reported no association between lung
Weight
(random) %
FEV1 % pred
(95% CI)
First author [ref.]
TOLUSAKOW, 1981 [71]
MOSSBERG, 1983 [65]
ELLERMAN, 1997 [56]
HELLINCKX, 1998 [59]
KARADAG, 1999 [61]
KOH, 2000 [62]
HORVATH, 2003 [60]
NOONE, 2004 [4]
MAHUT, 2006 [64]
OLM, 2011 [67]
AL SAADI, 2013 [51]
PAFF, 2013 [68]
VALLET, 2013 [72]
BOON, 2014 [53]
COHEN-CYMBERKNOH, 2014 [54]
GOKDEMIR, 2014 [58]
MAGLIONE, 2014 [63]
DAVIS, 2015 [55]
PIFFERI, 2015 [69]
YIALLOUROS, 2015 [73]
AMIRAV, 2016 [52]
SHAH, 2016 [70]
FRIJA-MASSON, 2017 [57]
NYILAS, 2017 [66]
55.70 (47.02–64.38)
62.00 (54.40–69.60)
66.75 (57.82–75.68)
64.00 (51.65–76.35)
75.00 (68.58–81.42)
83.70 (79.34–88.06)
51.00 (48.33–53.67)
69.00 (63.45–74.55)
75.19 (68.32–82.06)
74.60 (60.12–89.08)
80.07 (73.94–86.20)
95.90 (88.41–103.39)
79.30 (74.44–84.16)
79.98 (76.23–83.73)
85.00 (77.67–92.33)
72.90 (67.22–78.58)
82.48 (79.30–85.66)
83.80 (80.16–87.44)
84.00 (76.84–91.16)
71.24 (62.35–80.13)
58.92 (49.35–68.49)
71.50 (67.62–75.38)
70.35 (65.53–75.17)
91.40 (85.66–97.14)
4.0
4.1
4.0
3.6
4.2
4.4
4.5
4.3
4.2
3.3
4.2
4.1
4.3
4.4
4.1
4.3
4.4
4.4
4.2
4.0
3.9
4.4
4.3
4.3
21
24
24
11
21
19
14
78
16
10
22
25
41
122
14
24
158
118
45
20
13
118
78
49
Heterogeneity: I2=95.5%, τ2=153.61, p<0.0001
0 20 40
FEV1 % pred
60 80 100 120
74.49 (69.32–79.65) 100
Patients n
FIGURE 2 Forced expiratory volume in 1 s (FEV1) in primary ciliary dyskinesia patients: forest plot showing the heterogeneity and weighted mean
value of FEV1 % pred in the included studies.
https://doi.org/10.1183/23120541.00231-2018 7
PRIMARY CILIARY DYSKINESIA | F.S. HALBEISEN ET AL.
function decline and age of diagnosis [25, 63]. Preliminary results from 71 patients included in the
international PCD registry showed an annual mean decline of 0.59% in FEV1 % pred and of 0.39% in
FVC % pred [40]. Recent, smaller studies have evaluated the effect of managing lung function of PCD
patients with, for example, lobectomy [73] and endoscopic sinus surgery [18], without observing
significant differences in lung function decline.
Discussion
This is the first systematic review of lung function measurements of PCD patients. FEV1 was lower in
adults than children, but studies report a wide range of FEV1 and FVC values. This heterogeneity is not
accounted for by available explanatory factors. Of the 664 studies originally identified, only 9% reported
spirometry of PCD patients; 34 of the studies had overlapping study populations. Most studies were small,
with a mean of 49 patients per study, and less than half of the studies that included both children and
adults reported lung function stratified by age. Only two studies examined differences by sex. Reports of
spirometric indices were associated with the period of publication, provision of lung function reference
values and information on spirometry quality control. Not surprisingly, newer studies reported higher lung
function values.
The main strength of this study is in its methodology. We performed the search without language
restrictions and screened the full text of every identified clinical study with an original study population,
even if lung function was not explicitly mentioned in the abstract. This ensured that we included studies
Weight
(random) %
FEV1 % pred
(95% CI)
First author [ref.]
Patients ≥18 years old
Patients <18 years old
  MOSSBERG, 1983 [65]
  ELLERMAN, 1997 [56]
  HELLINCKX, 1998 [59]
  HORVATH, 2003 [60]
  NOONE, 2004 [4]
  MAHUT, 2006 [64]
  OLM, 2011 [67]
  FRIJA-MASSON, 2017 [57]
62.00 (54.40–69.60)
57.33 (43.77–70.89)
44.25 (26.25–62.25)
51.00 (48.33–53.67)
60.00 (58.86–61.14)
78.50 (64.79–92.21)
77.33 (65.78–88.88)
70.35 (65.53–75.17)
4.9
4.2
3.7
5.2
5.2
4.2
4.5
5.1
24
12
4
14
47
4
3
78
Heterogeneity: I2=98.4%, τ2=213.47, p<0.0001
  Heterogeneity: I2=78.4%, τ2=18.23, p<0.0001
0 20 40 60
FEV1 % pred
80 100 120
73.56 (67.03–80.08) 100
  Heterogeneity: I2=91.1%, τ2=50.34, p<0.0001 62.58 (56.71–68.46) 36.9
  ELLERMAN, 1997 [56]
  HELLINCKX, 1998 [59]
  KARADAG, 1999 [61]
  KOH, 2000 [62]
  NOONE, 2004 [4]
  MAHUT, 2006 [64]
  OLM, 2011 [67]
  AL SAADI, 2013 [51]
  PAFF, 2013 [68]
  VALLET, 2013 [72]
  GOKDEMIR, 2014 [58]
  MAGLIONE, 2014 [63]
  DAVIS, 2015 [55]
76.17 (66.81–85.53)
74.00 (66.69–81.31)
75.00 (68.58–81.42)
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FIGURE 3 Forced expiratory volume in 1 s (FEV1) in primary ciliary dyskinesia patients by age group: forest plot showing the heterogeneity and
weighted mean value of FEV1 % pred in the included studies.
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that a custom approach might miss. We contacted primary investigators of the included studies to acquire
spirometric indices in a consistent form in order to pool them in meta-analyses, and we separated our
results for paediatric and adult patients. We also accounted for heterogeneity in the results by performing
a meta-regression with all available explanatory factors. However, we were not able to include other factors
that were possibly known but not published in the studies. These include genetic variations in studied
populations, which are known to result in varying disease severity [52, 55], other indicators of disease
severity such as imaging data to assess structural changes in the lungs, and less well-documented clinical
factors such as compliance, adherence to therapy, age at diagnosis, and varying standards in clinical
surveillance and treatment (e.g. history of lobectomy and clinical status at the time of measurement).
We restricted our search to studies published since 1980 for several reasons. Many things have changed in
understanding and characterising PCD since it was first described by Kartagener in the early 1930s. Older
studies are often not available online or do not have an abstract in the online databases. In addition,
clinical studies of PCD before 1980 were mostly case reports or small studies with less than 10 patients
that were not eligible for our review.
Our review undoubtedly reflects the weaknesses of its included studies, most of which suffered from
significant selection bias. Its important limitations involve the differences in study designs and aims of the
included studies that might have directly influenced the lung function assessment of study populations.
Most studies used a convenience patient sample and did not describe how the participants were selected. It
is possible that in some cases patients with more severe respiratory problems were recruited whose lung
function might be more impaired. We did not perform a risk of bias assessment for the studies included
in this review. We expected all studies to suffer from moderate to serious risk, which is common in these
types of studies, especially in rare diseases, e.g. small studies mainly based on case series of patients. Our
most important limitation is that we could not compare the spirometric indices of the included studies
using the same reference values and, ideally, use z-scores for FEV1 and FVC. Unfortunately, the majority
of included studies reported percent predicted values derived from a variety of references. To address this
issue, we tested the particular lung function reference as a possible explanatory factor in the heterogeneity
in our meta-regression.
We do not expect significant diagnostic misclassification in the included studies, mainly because most studies
adhered to consensus guidelines and were published more recently [74]. However, misclassification bias is still
possible, especially for the older studies. When we repeated our meta-analyses excluding the two studies with
only clinical diagnoses the results did not change. As most studies suffered from the same design flaws, we did
not apply any quality assessment criteria to decide which studies to include in our meta-analysis.
Due to the considerable heterogeneity, the calculated mean weighted values of percent predicted FEV1 and
FVC should be interpreted with caution. The meta-analysis was performed to quantify the variability in
Weight
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(95% CI)
First author [ref.]
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ELLERMAN, 1997 [56]
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FIGURE 4 Forced vital capacity (FVC) in primary ciliary dyskinesia patients: forest plot showing the heterogeneity and weighted mean value of FVC
% pred in the included studies.
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reported spirometric indices and not to give valid estimates. The possible explanatory factors we tested
failed to explain this heterogeneity. Still, some factors contributed to explaining differences in FEV1 and
FVC in the included studies. Publication year may be indicative of differences in awareness and disease
diagnosis as well as changes in standardisation of treatment and routine surveillance of patients. Recent
studies are more likely to have used modern diagnostic approaches, and include more patients who are
correctly diagnosed and patients who have less severe disease and more genetic variations compared with
older studies. They also usually include patients treated with more modern treatment protocols, and use
newer and more correct spirometry reference values. Studies that did not report information on quality
control of spirometry data or lung function reference values might have had less strict protocols for lung
function measurements compared with studies that reported this information in detail. Although it was
not possible to pool the studies including repeated lung function measurements and study disease
progression over time, the reported percent predicted FEV1 was lower in adult patients compared with
children. On the one hand, this could support the progression of lung disease into adulthood; on the other
hand, differences between adults and children might also reflect differences in disease management or
diagnosis over the years.
Methodological variability in the studies we included could not explain the heterogeneity in lung function.
We believe that this heterogeneity is caused by factors that could not be tested in a meta-analysis given the
information that we had available (e.g. genetic factors, differences in disease management, factors related
to the variability of study inclusion criteria, and details on the performance and evaluation of lung
function measurements). This heterogeneity in lung function measurements goes hand in hand with the
heterogeneity we reported in our previous review on the clinical manifestations of PCD, which highlights
the limitations of published studies to describe the full clinical spectrum of PCD [3]. However, the results
of both reviews underline the possibility of distinctly different disease phenotypes, which also are observed
in other chronic respiratory diseases [75–77]. This is further supported by reports that link specific
ultrastructural defects and genetic mutations with more severe lung disease. In a study of North American
children with PCD, those with an absence of inner dynein arms in conjunction with central apparatus
defects and microtubular disorganisation associated with CCDC39 and CCDC40 mutations had lower
spirometric indices compared with other PCD patients [55]. Data from a smaller case series of Israeli
patients, analysed together with data from previous case reports, found that patients with CCNO mutations
showed rapid deterioration of lung function [52, 78, 79].
All these findings demonstrate the need for collaborative, prospective studies that use standardised
protocols for spirometry and international up-to-date reference values. To meet this need, together with a
network of international collaborators we are developing a standardised, disease-specific instrument for
patient follow-up and prospective data collection [80, 81]. At the same time, researchers in centres around
the world are conducting a prospective multicentre observational study of variability of lung function in
PCD patients (PROVALF-PCD) that will provide information on how FEV1 itself varies in individual
stable PCD patients [82].
Conclusions
Spirometric indices of PCD patients vary significantly between published studies, which not only suggests
the possibility of methodological differences between centres, but also real differences in disease
expression. Detailed characterisation of different PCD phenotypes in studies that use standardised outcome
measures and protocols, international up-to-date reference values, and, ideally, phenotype–genotype
associations are needed to explain this variability and to better understand the natural history of PCD.
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